$SNPS

Why Synopsys Stock Soared on Thursday

Synopsys (SNPS) stock rose 12.5% after the company projected 2027 revenue up to $11.2B, higher than analysts' $9.7B estimate for 2026. It expects 2027 free cash flow of $3.1B and operating margins of 20.7%. GAAP EPS is forecast at $8.16-$8.61, while non-GAAP EPS is projected at $19.04-$19.12.

Original reporting
Published Oct 1, 2026, 4:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 5:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Why Synopsys Stock Soared on Thursday — source image
Decision brief

The 30-second read

$SNPSBullishHigh
01

Why it matters

The guidance lift sparked a 12.5% intraday rally, indicating strong market reaction.

02

Market read

Guidance-driven rally highlights Synopsys as a short‑term buying opportunity.

03

What to watch

Potential headwinds from slower AI hardware spending could temper growth.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Synopsys held an Investor Day where it disclosed 2027 revenue guidance of $11.2 billion, far above consensus.

Company-level read

Ticker impact

$SNPSBullishHigh confidence
Context

Synopsys stock jumped 12.5% after Investor Day guidance of $11.2B revenue for 2027.

Expected impact

upward pressure as investors price in strong revenue outlook

Evidence & confidence

Guidance exceeds analyst expectations and triggered a sizable intraday rally.

Market effects

Positive signal for EDA and semiconductor design software sector.

U.S. tech stocks may see modest gains.

Limited to investors tracking AI‑related hardware and software supply chain.

Counterpoint

Some analysts may question the sustainability of non‑GAAP margins.

Key entities

  • Synopsys

    EDA software provider (NASDAQ:SNPS).

Related articles

$ACNMed

Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.

$SNPSMedAI 8/10

Synopsys Stock Jumps As AI Deals And Targets Power SNPS

Synopsys Inc. (NASDAQ: SNPS) stock rose 9.91% on October 1, 2026, driven by strong AI-chip design demand and upbeat guidance. The company reported $7.05B in trailing revenue, 72% gross margin, and guided to 15% annual revenue growth, targeting $11.15B in FY27. Recent partnerships with Amazon, OpenAI, and TSMC bolster its AI and chip design narrative. HSBC upgraded SNPS to Buy with a $700 target.

$SNPSHighAI 8/10

Synopsys Stock Jumps As AI Deals And Targets Impress Wall Street

Synopsys Inc. (NASDAQ: SNPS) shares rose 10.06% on October 1, 2026, driven by strong AI-chip design demand and upbeat guidance. The company reported $7.05B in revenue, 72.4% gross margin, and 30%+ EBITDA margin. SNPS projected 15% revenue growth for FY27, targeting $11.15B, and announced AI partnerships with Amazon and OpenAI. HSBC upgraded SNPS to Buy with a $700 target, citing high-growth AI potential.

$AMZNHighAI 9/10

Amazon Inks $1B SNPS Deal to Power AWS Custom Chips: Should You Hold?

Amazon signed a $1B+ deal with Synopsys to accelerate chip design for AWS, focusing on custom silicon. AWS's chips business exceeds $25B annual revenue, with Graviton and Trainium seeing strong adoption. AWS Q2 2026 revenue grew 37% YoY to $42.2B, with AI business also crossing $25B run rate. Amazon expects Q3 2026 sales of $197B-$202B and raised 2026 capex to $220B. AMZN shares up 6.8% YTD, despite cloud market competition.